What is the appropriate first‑line and second‑line treatment for seizures in a newborn?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: October 8, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Ask Question

Treatment of Neonatal Seizures

Phenobarbital is the recommended first-line antiseizure medication for neonatal seizures, regardless of etiology (HIE, stroke, or hemorrhage), with the exception of suspected channelopathy with positive family history where a sodium channel blocker should be used first. 1

First-Line Treatment Algorithm

Standard First-Line: Phenobarbital

  • Dose: 20 mg/kg IV loading dose
  • Efficacy: Controls seizures in approximately 80% of neonates when used as first-line therapy 1
  • Use for shortest duration possible with early discontinuation for acute provoked seizures responding to treatment, as phenobarbital has been associated with potential adverse effects including hypotension (17% incidence) 1

Exception - Suspected Channelopathy with Family History

  • If positive family history suggests self-limited familial neonatal epilepsy (KCNQ2/KCNQ3 variants), use phenytoin or carbamazepine (sodium channel blockers) as first-line instead 1
  • This avoids treatment delays while awaiting genetic confirmation
  • Without positive family history, still use phenobarbital first to avoid delays 1

Second-Line Treatment Algorithm

When seizures persist after first-line therapy, choice depends on clinical context:

For Most Etiologies (HIE, Stroke, Hemorrhage)

Phenytoin or levetiracetam are the preferred second-line options 1

  • Phenytoin: 39% response rate when added after phenobarbital 1
  • Levetiracetam: 54% response rate when added after phenobarbital 1
  • Less favorable alternatives: midazolam (0% in small trial) or lidocaine (60% response rate) 1

Special Clinical Scenarios

If channelopathy suspected by clinical/EEG features (without prior family history):

  • Use sodium channel blocker (phenytoin or carbamazepine) as second-line 1
  • Choice depends on clinical state (critically ill vs. stable) and regional drug availability 1

If cardiac disorders present:

  • Prefer levetiracetam as second-line to avoid cardiac effects of phenytoin 1

If vitamin B6-dependent epilepsy suspected (based on clinical/EEG features) OR seizures unresponsive to second-line without identified etiology:

  • Trial of pyridoxine (add-on to ASM) 1
  • If unsuccessful, trial of pyridoxal 5'-phosphate (PLP) may be considered 1
  • Do not delay treatment to collect diagnostic samples 1

Duration of Treatment

Discontinue ASM before hospital discharge following cessation of acute provoked seizures (electroclinical or electrographic) without evidence for neonatal-onset epilepsy, regardless of MRI or EEG findings 1

This represents a change from prior guidelines and is supported by evidence showing no difference in neurodevelopment or epilepsy at 24 months between neonates whose ASMs were discontinued versus continued at discharge 1

Critical Diagnostic Considerations

  • EEG or amplitude-integrated EEG (aEEG) confirmation is essential for reliable diagnosis 1
  • Only focal clonic and focal tonic seizures can be diagnosed by clinical observation alone; all other seizure types require EEG/aEEG confirmation 1
  • Many neonatal seizures are electrographic-only without clinical manifestations 2
  • Treatment of electrographic-only seizures to reduce seizure burden may be associated with improved outcomes, though direct evidence is limited 1

Common Pitfalls to Avoid

  1. Do not continue ASM beyond discharge for acute provoked seizures that have resolved, even with abnormal MRI or EEG background 1
  2. Do not use phenytoin in neonates with cardiac disorders 2
  3. Do not delay phenobarbital to pursue genetic testing unless there is a positive family history suggesting channelopathy 1
  4. Avoid emerging agents (oxcarbazepine, brivaracetam, lacosamide) as no controlled efficacy/safety data exist in neonates 1
  5. Recognize that partial response to ASM does not rule out vitamin B6-dependent epilepsy 1

Evidence Quality Note

The 2023 ILAE Task Force guidelines 1 represent the most comprehensive and recent evidence-based recommendations, superseding the 2011 WHO/ILAE/IBE guidelines. Evidence for first-line phenobarbital is moderate quality from RCTs, while second-line evidence remains very low quality with substantial variability across studies 1.

References

Related Questions

After stabilizing the infant following oxygenation, which secondary assessment steps should be performed, including chest X‑ray, evaluation for reversible causes of seizure, and electroencephalogram?
What is the recommended acute management of seizures in an infant, including initial stabilization, medication dosing, and necessary investigations?
What is the definition of a seizure?
How should airway management differ for a patient who is foaming at the mouth versus vomiting during an active seizure?
What are the return-to-work instructions for a patient who experienced a possible seizure and works operating heavy machinery, at elevated heights, and driving?
Is it safe and effective to apply minoxidil for only two hours and then rinse it off, assuming it has dried and been absorbed?
What are the recommended midazolam doses for different age groups (neonates, infants, children, adults, elderly) based on body weight?
Should I repeat MRSA (methicillin‑resistant Staphylococcus aureus) screening for a patient who tested negative three weeks ago but now presents with a new septic episode?
What is the pathophysiology of sitosterolemia?
Is a serum corrected calcium level of 9.2 mg/dL clinically significant?
Is there any correlation between an Escherichia coli urinary culture and extensive peripheral skin involvement?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.